HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

HAIXI PHARMA

166.000

-1.000-0.60%

Volume:86.40K

Turnover:14.67M

Market Cap:13.07B

PE:55.71

High:173.700

Open:167.100

Low:166.000

Close:167.000

52wk High:302.400

52wk Low:97.500

Shares:78.71M

HK Float Shares:78.71M

Volume Ratio:1.83

T/O Rate:0.11%

Dividend:- -

Dividend Rate:- -

EPS(LYR):2.980

ROE:16.58%

ROA:9.23%

PB:6.70

PE(LYR):55.71

PS:18.83

Loading ...

Overview Company News Filings

Fujian Haixi Pharma Wins FDA IND Clearance for Hx9428 Phase II nAMD Trial

Fujian Haixi Pharmaceuticals Co - U.S. FDA Approves Ind Application of Hx9428 for Neovascular Age-Related Macular Degeneration

THOMSON REUTERS

Personnel Shake-up at HAIXI PHARMA: New Executive Director Appointed

Fujian Haixi Pharma Shareholders Approved External Auditor Change at EGM

Fujian Haixi Pharmaceuticals Files Board, Board Committee Member List with Disclosure Roles

Fujian Haixi Pharmaceuticals Co - Elects Chen Tingze as Executive Director

THOMSON REUTERS

Fujian Haixi Pharma Discloses RMB 577.22 Million Investments Equal to 31.3% of 2025 Total Assets

Hong Kong Market Midday Update: Hang Seng Index Edges Up Slightly, Chip Stocks Lead Gains

Fujian Haixi Pharmaceuticals Announces First Extraordinary General Meeting

HAIXI PHARMA announces board reshuffle: Non-Executive Director Wang Xinkun resigns; Chen Tingze nominated as Executive Director

Bulletin Express

Fujian Haixi Pharmaceuticals Co - Nominates Chen Tingze as Candidate for Executive Director

THOMSON REUTERS

Fujian Haixi Pharmaceuticals Plans Auditor Switch to RSM China from Deloitte

Fujian Haixi Pharmaceuticals Gets China Nod for Glioblastoma Drug Trial

MT Newswires Live

HAIXI PHARMA secures NMPA IND approval for next-generation glioblastoma candidate HXP089

Bulletin Express

HAIXI PHARMA's HXP089 Project Receives NMPA Approval for Glioblastoma Clinical Trial Application

Fujian Haixi Pharma Says China NMPA Clears Hxp089 IND for Glioblastoma Trial

Fujian Haixi Pharmaceuticals Co - Nmpa Approves Ind Application for Hxp089 for Glioblastoma

THOMSON REUTERS

Fujian Haixi Pharma Begins Phase III Trial of Osteosarcoma Drug

MT Newswires Live

HAIXI PHARMA Records 2.01 Billion HKD in Deposited Securities, Major Shareholder Transfers Shares to CMB International

HAIXI PHARMA Initiates Phase III Trial for C019199 Tablets in Osteosarcoma

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/02637/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02637","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02637\",,,,,undefined,":{"symbol":"02637","market":"HK","secType":"STK","nameCN":"HAIXI PHARMA","latestPrice":166,"timestamp":1790755707004,"preClose":167,"halted":0,"volume":86400,"delay":0,"changeRate":-0.005988023952095809,"floatShares":78707270,"shares":78707270,"eps":2.9797622410546136,"marketStatus":"Closed National Day","change":-1,"latestTime":"09-30 16:08:27","open":167.1,"high":173.7,"low":166,"amount":14669567,"amplitude":0.046108,"askPrice":166.8,"askSize":250,"bidPrice":166,"bidSize":900,"shortable":3,"etf":0,"ttmEps":2.3333162610012557,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1790904600000},"marketStatusCode":7,"adr":0,"listingDate":1760889600000,"exchange":"SEHK","adjPreClose":167,"openAndCloseTimeList":[[1790731800000,1790740800000],[1790744400000,1790755200000]],"volumeRatio":1.8328383518955893,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02637\",,,,,undefined,":{"symbol":"02637","floatShares":78707270,"roa":"9.23%","roe":"16.58%","lyrEps":2.979762,"volumeRatio":1.8328383518955893,"shares":78707270,"dividePrice":0,"high":173.7,"amplitude":0.046108,"preClose":167,"low":166,"week52Low":97.5,"pbRate":"6.70","psRate":"18.83","week52High":302.4,"institutionHeld":0,"latestPrice":166,"committee":0.565217,"eps":2.9797622410546136,"divideRate":0,"volume":86400,"delay":0,"ttmEps":2.3333162610012557,"open":167.1,"prevYearClose":136,"prevWeekClose":172,"prevMonthClose":166,"prevQuarterClose":166,"fiveDayClose":175.6,"twentyDayClose":198.3,"sixtyDayClose":203},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02637\",params:#limit:5,,,undefined,":[{"date":"2026-08-28","symbol":"02637","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787880600000,"name":null,"time":"","dateTimestamp":1787846400000,"actualEps":null},{"date":"2026-03-30","symbol":"02637","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02637\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02637\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1781107200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02637\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02637","date":"2026-09-29","current":71.075055,"percent":0.577586,"low":41.43616,"twenty":68.636317,"median":73.094022,"eighty":82.099008,"high":108.687128,"avg":74.783937,"sd":9.267897,"marketCap":13144114090},"quantilePoints":[{"date":"2025-10-16","current":41.43616,"twenty":41.43616,"median":41.43616,"eighty":41.43616,"marketCap":6150186077},{"date":"2025-10-24","current":58.044665,"twenty":53.788314,"median":54.742854,"eighty":58.044665,"marketCap":8618446065},{"date":"2025-10-31","current":63.409996,"twenty":54.11413,"median":58.177187,"eighty":60.582738,"marketCap":9429130946},{"date":"2025-11-07","current":65.038519,"twenty":55.071217,"median":59.875924,"eighty":63.533346,"marketCap":9665252756},{"date":"2025-11-14","current":69.713569,"twenty":57.493757,"median":61.562796,"eighty":68.778725,"marketCap":10389359640},{"date":"2025-11-21","current":66.575785,"twenty":58.2567,"median":64.026746,"eighty":69.208194,"marketCap":9917116020},{"date":"2025-11-28","current":68.072175,"twenty":59.478322,"median":65.807152,"eighty":68.767812,"marketCap":10176850011},{"date":"2025-12-05","current":68.42835,"twenty":59.854834,"median":66.893861,"eighty":68.767812,"marketCap":10247686554},{"date":"2025-12-12","current":69.403659,"twenty":60.326406,"median":67.279459,"eighty":69.361692,"marketCap":10412971821},{"date":"2025-12-19","current":69.502155,"twenty":61.237436,"median":67.861589,"eighty":69.423358,"marketCap":10452325456},{"date":"2025-12-24","current":72.521094,"twenty":61.537644,"median":68.055113,"eighty":69.462757,"marketCap":10940310530},{"date":"2026-01-02","current":68.547,"twenty":62.032842,"median":68.254334,"eighty":69.697511,"marketCap":10381488913},{"date":"2026-01-09","current":76.256401,"twenty":63.533346,"median":68.54394,"eighty":70.33117,"marketCap":11577839417},{"date":"2026-01-16","current":83.450154,"twenty":64.030428,"median":68.594109,"eighty":71.180851,"marketCap":12711224105},{"date":"2026-01-23","current":75.203122,"twenty":64.243828,"median":68.851274,"eighty":73.407226,"marketCap":11444037058},{"date":"2026-01-30","current":72.029156,"twenty":65.345972,"median":69.26967,"eighty":73.580372,"marketCap":11011147073},{"date":"2026-02-06","current":69.741329,"twenty":66.631937,"median":69.18814,"eighty":73.524909,"marketCap":10688447266},{"date":"2026-02-13","current":69.700471,"twenty":66.864009,"median":69.376262,"eighty":73.289662,"marketCap":10743542355},{"date":"2026-02-20","current":69.085102,"twenty":66.878935,"median":69.376262,"eighty":72.984771,"marketCap":10633352177},{"date":"2026-02-27","current":72.331605,"twenty":67.046254,"median":69.403659,"eighty":72.584608,"marketCap":11255139610},{"date":"2026-03-06","current":63.89376,"twenty":67.046254,"median":69.448144,"eighty":72.584608,"marketCap":9862020931},{"date":"2026-03-13","current":75.4784,"twenty":67.193436,"median":69.633279,"eighty":73.562991,"marketCap":11703771049},{"date":"2026-03-20","current":69.956787,"twenty":67.26348,"median":69.715081,"eighty":73.483508,"marketCap":10806508171},{"date":"2026-03-27","current":78.768036,"twenty":67.31702,"median":69.741329,"eighty":73.616705,"marketCap":12136661034},{"date":"2026-04-02","current":69.050489,"twenty":67.448055,"median":69.756887,"eighty":73.953025,"marketCap":13907574609},{"date":"2026-04-10","current":75.734842,"twenty":67.617502,"median":69.89051,"eighty":74.51958,"marketCap":15371529831},{"date":"2026-04-17","current":75.664292,"twenty":67.861589,"median":70.029272,"eighty":74.51958,"marketCap":15363659104},{"date":"2026-04-24","current":92.094347,"twenty":68.038051,"median":70.361759,"eighty":74.892793,"marketCap":18700847352},{"date":"2026-04-30","current":101.138303,"twenty":68.06535,"median":70.518529,"eighty":75.515578,"marketCap":20542597470},{"date":"2026-05-08","current":91.134409,"twenty":68.133872,"median":70.614497,"eighty":76.472636,"marketCap":18574915720},{"date":"2026-05-15","current":84.578883,"twenty":68.178204,"median":70.813553,"eighty":78.193464,"marketCap":17284116492},{"date":"2026-05-22","current":93.496946,"twenty":68.295676,"median":71.108793,"eighty":80.407586,"marketCap":19062900794},{"date":"2026-05-29","current":86.09458,"twenty":68.386305,"median":71.340959,"eighty":80.936301,"marketCap":17614687026},{"date":"2026-06-05","current":72.717092,"twenty":68.497704,"median":72.103769,"eighty":80.766638,"marketCap":14899286211},{"date":"2026-06-12","current":67.961351,"twenty":68.497704,"median":71.340959,"eighty":80.580489,"marketCap":13915445336},{"date":"2026-06-18","current":66.149737,"twenty":68.365282,"median":71.108793,"eighty":80.547429,"marketCap":13577004075},{"date":"2026-06-26","current":64.123676,"twenty":68.103023,"median":70.813553,"eighty":80.470686,"marketCap":13096889728},{"date":"2026-07-03","current":76.78307,"twenty":68.156523,"median":70.813553,"eighty":80.277662,"marketCap":15694229638},{"date":"2026-07-10","current":79.190679,"twenty":68.212992,"median":71.108793,"eighty":80.277662,"marketCap":16166473258},{"date":"2026-07-17","current":71.84101,"twenty":68.34426,"median":71.590985,"eighty":79.86919,"marketCap":14718259490},{"date":"2026-07-24","current":70.518964,"twenty":68.451468,"median":71.287767,"eighty":79.796901,"marketCap":14450654772},{"date":"2026-07-31","current":65.554893,"twenty":68.149296,"median":70.906272,"eighty":79.747346,"marketCap":13458943170},{"date":"2026-08-07","current":75.261161,"twenty":68.149296,"median":71.19828,"eighty":79.190679,"marketCap":15481720009},{"date":"2026-08-14","current":78.261297,"twenty":68.185431,"median":71.340959,"eighty":78.768036,"marketCap":16119248896},{"date":"2026-08-21","current":76.639812,"twenty":68.323237,"median":72.054899,"eighty":79.190679,"marketCap":15820161270},{"date":"2026-08-28","current":74.907011,"twenty":68.42835,"median":72.201471,"eighty":78.768036,"marketCap":15465978555},{"date":"2026-09-04","current":89.46632,"twenty":68.54394,"median":72.352576,"eighty":79.884165,"marketCap":15686358911},{"date":"2026-09-11","current":86.521471,"twenty":68.545014,"median":72.521094,"eighty":80.616434,"marketCap":15190503110},{"date":"2026-09-18","current":86.274256,"twenty":68.547,"median":72.698486,"eighty":82.359485,"marketCap":15166890929},{"date":"2026-09-25","current":77.153646,"twenty":68.63305,"median":72.884321,"eighty":82.34846,"marketCap":13537650440},{"date":"2026-09-29","current":74.80688,"twenty":68.636317,"median":73.094022,"eighty":82.099008,"marketCap":13144114090}],"updateTime":1790809209468},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02637\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2656853990","title":"Fujian Haixi Pharma Wins FDA IND Clearance for Hx9428 Phase II nAMD Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2656853990","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656853990?lang=en_us&edition=fundamental","pubTime":"2026-08-04 17:13","pubTimestamp":1785834780,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharma wins FDA IND clearance for HX9428 Phase II nAMD trialFujian Haixi Pharmaceuticals secured US FDA IND clearance to start a Phase II trial of oral nAMD candidate HX9428 in the US.Chi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL356fXN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0109394709.USD","LU0889565916.HKD","LU2362540622.SGD","LU2023250504.SGD","LU2468319806.SGD","LU2089984988.USD","LU0058720904.USD","LU2106854487.HKD","02637","LU1974910355.USD","BK4139","BK4588","BBH","LU0053666078.USD","IBB","LU0823434583.USD","IBBQ","LU0823434740.USD","LU0289739699.SGD","LU1917777945.USD","LU2362541513.USD","BK1191","LU0823416689.USD","TBXU","LU0882574055.USD","REGN","BK4585","LU2362541273.HKD","LU0114720955.EUR","LU2237438978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656399215","title":"Fujian Haixi Pharmaceuticals Co - U.S. FDA Approves Ind Application of Hx9428 for Neovascular Age-Related Macular Degeneration","url":"https://stock-news.laohu8.com/highlight/detail?id=2656399215","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656399215?lang=en_us&edition=fundamental","pubTime":"2026-08-04 17:12","pubTimestamp":1785834779,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nFWN4401O6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173965034","title":"Personnel Shake-up at HAIXI PHARMA: New Executive Director Appointed","url":"https://stock-news.laohu8.com/highlight/detail?id=1173965034","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173965034?lang=en_us&edition=fundamental","pubTime":"2026-08-04 17:00","pubTimestamp":1785834013,"startTime":"0","endTime":"0","summary":"HAIXI PHARMA (02637) has announced a change in its board composition following the conclusion of its extraordinary general meeting.Mr. Wang Xinkun has retired from his position as a director of the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656536091","title":"Fujian Haixi Pharma Shareholders Approved External Auditor Change at EGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2656536091","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656536091?lang=en_us&edition=fundamental","pubTime":"2026-08-04 16:55","pubTimestamp":1785833728,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharma shareholders approved external auditor change at EGMFujian Haixi Pharmaceuticals held an extraordinary general meeting on Aug. 4, 2026.Shareholders backed a change of external audi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDLb7w91Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656536019","title":"Fujian Haixi Pharmaceuticals Files Board, Board Committee Member List with Disclosure Roles","url":"https://stock-news.laohu8.com/highlight/detail?id=2656536019","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656536019?lang=en_us&edition=fundamental","pubTime":"2026-08-04 16:55","pubTimestamp":1785833717,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals files board, board committee member list with disclosure rolesFujian Haixi Pharmaceuticals set out its board and committee line-up in a disclosure dated Aug. 4, 2026.Executive directors: Chairman Dr. Kang Xinshan, Feng Yan, Dr. Chen Guangming, Li Junqing, Chen Tingze.Non-executive director: Xu Dong; independent non-executive directors: Lin Bin, Wang Shanshan, Pu Meiting.Committee chairs: Pu Meiting , Wang Shanshan , Dr. Kang .Other committee memberships include Dr. Kang , Feng Yan , Lin Bin , Pu Meiting .Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fujian Haixi Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL3GxQ6x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656536726","title":"Fujian Haixi Pharmaceuticals Co - Elects Chen Tingze as Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2656536726","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656536726?lang=en_us&edition=fundamental","pubTime":"2026-08-04 16:54","pubTimestamp":1785833677,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nFWN441071:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656321728","title":"Fujian Haixi Pharma Discloses RMB 577.22 Million Investments Equal to 31.3% of 2025 Total Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2656321728","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656321728?lang=en_us&edition=fundamental","pubTime":"2026-08-03 16:33","pubTimestamp":1785746009,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharma discloses RMB 577.22 million investments equal to 31.3% of 2025 total assetsFujian Haixi Pharmaceuticals issued a supplemental clarification to its 2025 annual report, detailing fi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDLbvfCBf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186254975","title":"Hong Kong Market Midday Update: Hang Seng Index Edges Up Slightly, Chip Stocks Lead Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=1186254975","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186254975?lang=en_us&edition=fundamental","pubTime":"2026-07-21 12:16","pubTimestamp":1784607377,"startTime":"0","endTime":"0","summary":"The Hong Kong market showed mixed movements at the midday break. The benchmark Hang Seng Index registered a marginal increase of 0.03%, adding 7 points to reach 25,150. In contrast, the Hang Seng...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359201885.HKD","LU0359202008.SGD","SG9999004220.SGD","LU0359201612.USD","LU0593848301.USD","07300","BK1548","07200","HSTECH","LU2351347302.SGD","03088","02689","03423","BK1610","03339","BK1190","513600","01888","03858","LU0708995583.HKD","LU1211504680.USD","02800","03067","01347","09088","LU0052750758.USD","HSImain","LU0384037296.USD","BK1117","BK1171","02837","03277","SG9999002950.SGD","06880","MCHmain","NDGPY","HSI","603986","HK0000252152.HKD","BK1181","LKHLY","BK1223","BK1191","LU2039709279.SGD","02833","07552","03417","BK1163","KBDCY","82800","LU1808992512.USD","IE0034224299.USD","300450","SG9999006597.SGD","BK1551","03419","BK1607","BK1183","LU1813983027.USD","02513","03037","HK0000252160.HKD","LU0648948544.HKD","HK0000500386.USD","MCHS","LU1282649810.SGD","LU1282649067.USD","00470","07500","BK1170","LU1328277881.USD","02637","TCHI","LU1023057109.AUD","BK1526","00100","688347","LU0320764599.SGD","SG9999001093.SGD","BK1179","03033","LU0314109678.HKD","HTImain","09115","03115","00148","688981","09067","WOOD","LU0488056044.USD","BK1514","BK1505","00981","FPA","03986","BK1506","LU2929501877.USD","83115","SG9999014674.SGD","03032","HHImain","LU2187417386.USD","07226","BK1614","BK1589","LU1282649141.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651452644","title":"Fujian Haixi Pharmaceuticals Announces First Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2651452644","media":"Reuters","labels":["conferences","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651452644?lang=en_us&edition=fundamental","pubTime":"2026-07-15 18:43","pubTimestamp":1784112224,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals announces first extraordinary general meetingFujian Haixi Pharmaceuticals will hold a first extraordinary general meeting in Fuzhou, China on Aug. 4, 2026.Shareholders wil","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL7wllK0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176589941","title":"HAIXI PHARMA announces board reshuffle: Non-Executive Director Wang Xinkun resigns; Chen Tingze nominated as Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1176589941","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176589941?lang=en_us&edition=fundamental","pubTime":"2026-07-15 18:41","pubTimestamp":1784112119,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (“HAIXI PHARMA”) reported that Non-Executive Director Wang Xinkun will step down once shareholders elect a replacement at an upcoming general meeting. The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651454014","title":"Fujian Haixi Pharmaceuticals Co - Nominates Chen Tingze as Candidate for Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2651454014","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651454014?lang=en_us&edition=fundamental","pubTime":"2026-07-15 18:35","pubTimestamp":1784111752,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nFWN43H052:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651745403","title":"Fujian Haixi Pharmaceuticals Plans Auditor Switch to RSM China from Deloitte","url":"https://stock-news.laohu8.com/highlight/detail?id=2651745403","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651745403?lang=en_us&edition=fundamental","pubTime":"2026-07-15 18:33","pubTimestamp":1784111625,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals plans auditor switch to RSM China from DeloitteFujian Haixi Pharmaceuticals will switch financial reporting to China Accounting Standards for Business Enterprises from its","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL4SPz0X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651293174","title":"Fujian Haixi Pharmaceuticals Gets China Nod for Glioblastoma Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2651293174","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651293174?lang=en_us&edition=fundamental","pubTime":"2026-07-14 18:20","pubTimestamp":1784024435,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals (HKG:2637) obtained approval for an investigational new drug application for a clinical trial of HXP089.The drug has been developed by the company to treat glioblastoma, according to a Tuesday Hong Kong bourse filing.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142109509","title":"HAIXI PHARMA secures NMPA IND approval for next-generation glioblastoma candidate HXP089","url":"https://stock-news.laohu8.com/highlight/detail?id=1142109509","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142109509?lang=en_us&edition=fundamental","pubTime":"2026-07-14 17:20","pubTimestamp":1784020849,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA) has received Investigational New Drug (IND) approval from China’s National Medical Products Administration (NMPA) for HXP089, a selective...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116749786","title":"HAIXI PHARMA's HXP089 Project Receives NMPA Approval for Glioblastoma Clinical Trial Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1116749786","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116749786?lang=en_us&edition=fundamental","pubTime":"2026-07-14 17:13","pubTimestamp":1784020411,"startTime":"0","endTime":"0","summary":"The company's self-developed HXP089 project, intended for the treatment of glioblastoma (GBM), has received approval for its Investigational New Drug (IND) application from the Center for Drug...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","IND","02637","BMED","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651176958","title":"Fujian Haixi Pharma Says China NMPA Clears Hxp089 IND for Glioblastoma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2651176958","media":"Reuters","labels":["productRelease","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651176958?lang=en_us&edition=fundamental","pubTime":"2026-07-14 17:08","pubTimestamp":1784020117,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharma says China NMPA clears HXP089 IND for glioblastoma trialFujian Haixi Pharmaceuticals secured NMPA clearance for an IND for HXP089 in glioblastoma, enabling clinical trials in China","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nNDL59l4vF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Fujian Haixi Pharma Says China NMPA Clears Hxp089 IND for Glioblastoma Trial","news_tag":"productRelease,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651769371","title":"Fujian Haixi Pharmaceuticals Co - Nmpa Approves Ind Application for Hxp089 for Glioblastoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2651769371","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651769371?lang=en_us&edition=fundamental","pubTime":"2026-07-14 17:08","pubTimestamp":1784020083,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nFWN43G0ES:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650118498","title":"Fujian Haixi Pharma Begins Phase III Trial of Osteosarcoma Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2650118498","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650118498?lang=en_us&edition=fundamental","pubTime":"2026-07-10 18:40","pubTimestamp":1783680005,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals  officially began a phase III clinical trial of the C019199 tablets, according to a Friday Hong Kong bourse filing.The trial aims to evaluate the efficacy and safety of the drug for the treatment of osteosarcoma after the failure of at least two prior lines of therapy.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","III","BK4134","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152440435","title":"HAIXI PHARMA Records 2.01 Billion HKD in Deposited Securities, Major Shareholder Transfers Shares to CMB International","url":"https://stock-news.laohu8.com/highlight/detail?id=1152440435","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152440435?lang=en_us&edition=fundamental","pubTime":"2026-07-10 09:02","pubTimestamp":1783645348,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, a significant position change occurred for HAIXI PHARMA (02637) on July 9th. The total value of securities deposited reached 2.013...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161027","BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170255563","title":"HAIXI PHARMA Initiates Phase III Trial for C019199 Tablets in Osteosarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1170255563","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170255563?lang=en_us&edition=fundamental","pubTime":"2026-07-09 16:42","pubTimestamp":1783586555,"startTime":"0","endTime":"0","summary":"HAIXI PHARMA (ASX: 02637) has announced the official commencement of a Phase III clinical trial (CTR20261818) for its self-developed C019199 tablets, targeting osteosarcoma patients who have failed...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["III","BK1191","BK4134","IBBQ","02637","BMED"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":73,"code":"91000000","status":"200"}]}}